221 related articles for article (PubMed ID: 12482130)
21. A clinical analysis on functioning pancreatic neuroendocrine tumors (focusing on VIPomas): a single-center experience.
Murakami M; Fujimori N; Matsumoto K; Ohno A; Teramatsu K; Takamatsu Y; Takeno A; Ueda K; Oono T; Ito T; Ogawa Y
Endocr J; 2022 Oct; 69(10):1201-1209. PubMed ID: 35644576
[TBL] [Abstract][Full Text] [Related]
22. A case of vasoactive intestinal polypeptideoma.
Sycamnias J; Strahl B; Stride P; Chern B; Paranavithana L
N Z Med J; 2009 Jun; 122(1296):64-8. PubMed ID: 19652683
[No Abstract] [Full Text] [Related]
23. [Transcatheter embolization of metastatic liver VIPoma: report of a case].
Ito S; Kasturagi M; Otsuji H; Ohishi H; Uchida H; Nakano H; Yabuta M; Ishikawa H
Rinsho Hoshasen; 1987 Oct; 32(10):1169-72. PubMed ID: 2832643
[No Abstract] [Full Text] [Related]
24. Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.
Schizas D; Mastoraki A; Bagias G; Patras R; Moris D; Lazaridis II; Arkadopoulos N; Felekouras E
J BUON; 2019; 24(2):415-423. PubMed ID: 31127985
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
Williams G; Anderson JV; Williams SJ; Bloom SR
Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
[TBL] [Abstract][Full Text] [Related]
26. A case of vasoactive intestinal peptide-secreting tumor (VIPoma) arising from MEN1 inactivation which recurred 15 years after the initial resection.
Sakurai M; Wakabayashi T; Kondo Y; Ikeda E; Watanabe K; Takei A; Okazaki H; Okada K; Ebihara K; Kakiuchi N; Ogawa S; Fukushima N; Ishibashi S
Endocr J; 2023 Jun; 70(6):573-579. PubMed ID: 36889692
[TBL] [Abstract][Full Text] [Related]
27. Skin metastasis of pancreatic vasoactive intestinal polypeptide tumor: case report and review of the literature.
Ram R; Natanzi N; Saadat P; Eliav D; Vadmal MS
Arch Dermatol; 2006 Jul; 142(7):946-7. PubMed ID: 16847229
[No Abstract] [Full Text] [Related]
28. Successful Treatment of Hypokalemic Rhabdomyolysis Caused by a Pancreatic VIPoma: A Case Report.
Ramirez S; Lytle M; Togores E; Parellada J; Carlan SJ; Madruga M; Murillo-Alvarez RM
Am J Case Rep; 2019 Nov; 20():1723-1727. PubMed ID: 31754090
[TBL] [Abstract][Full Text] [Related]
29. Clinical problem-solving. Needle in a haystack.
Kapoor R; Moseley RH; Kapoor JR; Crapo LM; Saint S
N Engl J Med; 2009 Feb; 360(6):616-21. PubMed ID: 19196679
[No Abstract] [Full Text] [Related]
30. Life threatening diarrhoea ultimately cured by surgery.
Sjöqvist U; Permert J; Löfberg R; Larsson J; Gadaleanu V; Adrian TE
Eur J Gastroenterol Hepatol; 1998 Nov; 10(11):963-7. PubMed ID: 9872620
[TBL] [Abstract][Full Text] [Related]
31. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma.
Moug SJ; Leen E; Horgan PG; Imrie CW
Pancreatology; 2006; 6(1-2):155-9. PubMed ID: 16354964
[TBL] [Abstract][Full Text] [Related]
32. [Diagnosis and treatment of vasoactive intestinal peptide-secreting-tumors: one case report and 15 years review in China].
Li JT; Peng SY; Liu YB; Fang HQ; Wu YL; Wang XB; Tang Z; Qian HR; Ji C
Zhonghua Wai Ke Za Zhi; 2004 May; 42(9):524-7. PubMed ID: 15196363
[TBL] [Abstract][Full Text] [Related]
33. Hypokalemic rhabdomyolysis due to watery diarrhea, hypokalemia, achlorhydria (WDHA) syndrome caused by vipoma.
Kibria R; Ahmed S; Ali SA; Barde CJ
South Med J; 2009 Jul; 102(7):761-4. PubMed ID: 19488018
[TBL] [Abstract][Full Text] [Related]
34. [Pancreatic VIPoma. Report of one case].
Urdangarin A; Iñiguez G; Benavides C; Castillo C; Castro A; Castillos I; Corredoira Y; Soto N
Rev Med Chil; 2010 Jul; 138(7):841-6. PubMed ID: 21043079
[TBL] [Abstract][Full Text] [Related]
35. An Unusual Cause of Watery Diarrhea.
Nassani N; Melitas C; Villa E
Gastroenterology; 2021 Feb; 160(3):671-674. PubMed ID: 33039475
[No Abstract] [Full Text] [Related]
36. [A long-term survival case of recurrent pancreatic vipoma with liver metastases treated by a combination of surgical resection and loco-regional therapies].
Matsukawa H; Fujiwara Y; Shiozaki S; Takakura N; Aoki H; Ohno S; Ojima Y; Harano M; Kanazawa T; Choda Y; Ninomiya M
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2158-60. PubMed ID: 22202315
[TBL] [Abstract][Full Text] [Related]
37. Percutaneous Irreversible Electroporation for Pancreatic VIPoma: A Case Report.
Niu L; Li J; Zeng J; Fang G; Zhou L; Xu K; Zhang K
Pancreas; 2017 Jan; 46(1):135-137. PubMed ID: 27977628
[TBL] [Abstract][Full Text] [Related]
38. [Vipoma in an adolescent: treatment with a delayed-action somatostatin analog, octreotide or SMS 201-995, and surgical removal].
Brichard B; Fiasse R; Buts JP; Clapuyt P; Maes M; Rahier J; Cornu G
Acta Gastroenterol Belg; 1990; 53(2):188-97. PubMed ID: 2176428
[TBL] [Abstract][Full Text] [Related]
39. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation.
Cho KJ; Vinik AI
Radiology; 1990 Nov; 177(2):549-53. PubMed ID: 2171015
[TBL] [Abstract][Full Text] [Related]
40. Giant metastatic VIPoma in the liver.
Dohmen K; Fukushima N; Fujisaki T; Iwakiri R; Yamano Y; Nagano M; Wada K; Kodama K; Iwata Y; Hachimine K
Gastroenterol Jpn; 1991 Aug; 26(4):530-5. PubMed ID: 1655553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
